Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder
The goal of this clinical trial is to examine whether individuals with co-occurring opioid use disorder and alcohol use (OUD+ALC) experience heightened pain sensitivity, pain-related negative affect, and greater alcohol reinforcement compared with alcohol-only (ALC) or opioid-only (OUD-ALC) users.
The main questions it aims to answer are:
- Aim 1. Do individuals with OUD+ALC experience increased pain and pain-related negative affect during periods of sobriety relative to mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
- Aim 2. Do individuals with OUD+ALC experience greater alcohol-induced analgesia and alcohol reinforcement compared with mono-users of alcohol (ALC only) and opioids (OUD-ALC)?
Participants will:
- Complete a screening session
- Complete one lab session including a comprehensive assessment battery involving multimodal assessments of pain during sobriety
- Complete two experimental lab sessions that will include intravenous (IV) administration of either 80mg% alcohol or placebo (saline), order counterbalanced, to measure alcohol's acute effects on pain and pain-related negative affect
研究概览
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习联系方式
- 姓名:Stephanie Gorka, PhD
- 电话号码:614-366-1027
- 邮箱:stephanie.gorka@osumc.edu
学习地点
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University
-
接触:
- Stephanie Gorka, PhD
- 电话号码:614-366-1027
- 邮箱:stephanie.gorka@osumc.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
ALC Only Group:
- 21-65 years old
- Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
OUD + ALC Group:
- 21-65 years old
- Required to meet NIAAA criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week)
- Meet DSM-5 criteria for current opioid use disorder (OUD)
- Report using recreational opioids at least weekly (past month)
OUD-ALC Group:
- 21-65 years old
- Meet DSM-5 criteria for current OUD
- Report using recreational opioids at least weekly (past month)
- Meet "light drinking" criteria (consuming equal to or less than 4 drinks per week for women or consuming equal to or less than 5 drinks per week for men)
- Report at least 1 but no more than 3 binge episodes over the past 12 months
Exclusion Criteria:
- Serious medical problems
- Current medical or psychiatric conditions requiring medication for which alcohol is contraindicated (including prescription opioids)
- Any serious medical problems
- Sensitivity or allergy to alcohol
- Body weight < 110 or > 210 lbs for alcohol administration
- Injury, trauma, nerve/tissue damage, or deformity prohibiting sensory testing
- Moderate to severe substance use disorders other than alcohol use disorder (AUD) or OUD
- Current severe mental illness, including mania or psychosis
- Currently seeking inpatient/intensive treatment for addictive behaviors
- Pregnant or nursing and unwilling to take measures to avoid becoming pregnant during the study (females)
- Chronic pain requiring ongoing pain management within the past three months.
- Clinically significant alcohol or opioid withdrawal symptoms the day of the lab sessions, defined as a score >10 on the Clinical Institute Withdrawal Assessment of Alcohol Scale Revised (CIWA-Ar) or a score >12 on the Clinical Opioid Withdrawal Scale (COWS)
- Positive alcohol breath test or opioid urine screen the day of the experimental lab sessions to avoid the potential for alcohol-opioid interactions.
- Smoking more than 6 cigarettes per day (or alternative form equivalent)
- Not fluent in English
学习计划
研究是如何设计的?
设计细节
- 主要用途:基础科学
- 分配:非随机化
- 介入模型:交叉作业
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Alcohol (ALC) Only Group
Participants in this group will be required to meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week). |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
|
其他:Opioid Use Disorder (OUD) + ALC Group
Participants in this group will be required to 1) Meet the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for heavy drinking (Male: Consuming 5 or more drinks on any day or 15 or more per week; Female: consuming 4 or more on any day or 8 or more drinks per week); 2) Meet DSM-5 criteria for current OUD and; 3) Report using recreational opioids at least weekly (past month). |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
|
其他:OUD-ALC Group
Participants in this group will be required to 1) Meet DSM-5 criteria for current OUD; 2) Report using recreational opioids at least weekly (past month); 3) Meet "light drinking" criteria (consuming less than or equal to 4 alcoholic drinks per week (female) or less than or equal to 5 alcoholic drinks (men) and; 4) Report at least 1 but no more than 3 binge episodes over the past 12 months. |
Participants will receive 80 mg% intravenous alcohol and saline. Participants receive placebo (saline) intravenously. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pain intensity during the pressure task, measured using a visual analog scale (VAS)
大体时间:Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Pain intensity will be reported during the pressure task administered during each of the three laboratory sessions (Baseline, Placebo, and Alcohol). Participants will rate their perceived pain intensity using a numerical rating scale ranging from 0-100. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Pain pressure threshold during the pressure task
大体时间:Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Pain pressure threshold is estimated by averaging reports across the different runs of the pressure task that is administered at all three lab sessions. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Startle eyeblink potentiation during the anticipation task
大体时间:Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
Startle eyeblink potentiation will be collected during the anticipation task that is administered at all three lab sessions. Startle is a cross-species index of aversive reactivity. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Self-reported affect during the anticipation task
大体时间:Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
At the end of the anticipation task, participants will rate how intense, arousing, and anxiety-provoking the task was on a 1-to-10 scale, with 1 indicating low intensity, arousal, or anxiety and 10 indicating high intensity, arousal, or anxiety. |
Baseline (Visit 1), approximately 7 days later (Visit 2), and approximately 14 days after baseline (Visit 3)
|
|
Subjective affective response to alcohol in the lab
大体时间:Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will complete the Profile of Mood States (POMS) throughout the placebo and alcohol administration protocols. The individual mood states will be examined and compared across sessions. Higher scores on each POMS subscale indicate a greater degree of the corresponding mood state, while lower scores indicate a lesser degree of that mood state. |
Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Subjective effects of alcohol in the lab
大体时间:Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
Participants will rate the degree to which they "feel", "like", and "want more" of the infused substance on a visual analog scale ranging from 0 to 100. The "like" and "want more" scales will serve as the primary measures of alcohol liking and wanting, respectively. |
Placebo and Alcohol sessions (Visits 2 and 3), approximately 7 days apart.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- STUDY20252506
- 1R21AA032964-01 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
De-identified data, including startle eyeblink and behavior, from this project will be submitted to the The National Institute on Alcohol Abuse and Alcoholism Data Archive (NIAAADA) at the subject level along with appropriate supporting documentation to enable efficient use of the data by the research community. We will follow instructions as discussed in the NDA Data Sharing Terms and Conditions.
IPD 共享时间框架
The data will be submitted biannually.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.